1453170-69-8

Upstream product

• 170220-11-8 5-azido-1-pentanol 
• 1200763-56-9 4-methylphenyl 2,3-di-O-benzyl-4,6-O-di-tert-butylsilanediyl-1-thio-β-D-galactopyranoside 

Downstream Products

• 1453170-70-1 2,3-O-di-benzyl-1-O-(5-azidopenty)-α-D-galactopyranoside 
• 1453170-71-2 2,3,4-O-tri-benzyl-1-O-(5-azidopenty)-α-D-galactopyranoside 

Relevant academic research and scientific papers

GLYCAN CONJUGATES AND USE THEREOF

Described herein are synthetic glycan conjugates comprising a carrier and a glycan moiety derived from Neisseria meningitidis, wherein the glycan moiety is covalently linked to the carrier through a linker. Also provided herein are a mixture of the glycan conjugates thereof, immmunogenic compositions thereof, and kits thereof. The invention further provides methods of using the synthetic glycan conjugates and immunogenic compositions thereof to treat and/or reduce the risk of infectious diseases such as bacterial infections.

Synthesis of Neisseria meningitidis serogroup W135 capsular oligosaccharides for immunogenicity comparison and vaccine development

Sweetening the deal: N.meningitidis serogroup W135 capsular oligosaccharides were synthesized in lengths from disaccharides to decasaccharides. Sera from mice immunized with these oligosaccharide-protein conjugates were examined by a glycan microarray (see picture) and bactericidal assay for antibody specificity and the ability to kill bacteria. Copyright